• VENKATASWAMY R Department of Pharmaceutics, The Oxford College of Pharmacy, Bengaluru, Karnataka, India.
  • LAVANYA NALLAGUNTLA Department of Pharmaceutics, The Oxford College of Pharmacy, Bengaluru, Karnataka, India.


Pulsatile drug delivery systems (PDDS) are acquiring a lot of interest as they deliver the medication at the perfect place at the perfect time and in the perfect amount, subsequently giving spatial and transient delivery and increasing patient consistency. These systems are designed by the circadian rhythm of the body. The primary reasoning for the utilization of pulsatile arrival of the medications is the place where a consistent medication release is not desired. A pulse must be planned so that a complete and rapid medication release is accomplished after the lag time. A different system such as capsular system, osmotic system, single-and multiple unit system dependent on the utilization of soluble or erodible polymer coating, and the utilization of rupturable films has been managed in the article. It sums up the most recent technology development, formulation parameter, and delivery profiles of this system. PDDS is helpful for the medications having chronopharmacological conduct where night-time dosing is required, such as anti-arrhythmic, anti-ulcerative, and anti-asthmatic, and so on The momentum survey article talked about the explanations behind the advancement of the PDDS, benefits, limitation, mechanism of medication release, need for pulsatile drug delivery, a disease that requires pulsatile technology, classification, and future parts of PDDS.

Keywords: Pulsatile drug delivery system, Press-coated, Methodologies, Marketed technologies, Biological rhythm


1. Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug delivery systems. Biomatter 2011;1:57-65.
2. Patel VP, Soniwala M. Pulsatile drug delivery system for treatment of various inflammatory disorders. Int J Drug Dev 2012;3:67-87.
3. Mohd AH, Raghavendra RN. Novel technologies in formulations. World J Pharm Res 2012;1:1-17.
4. Bussemer T, Peppas NA, Bodmeier R. Evaluation of the swelling, hydration, and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system. Eur J Pharm Biopharm 2003;56:261-70.
5. Maroni A, Zema L, Loreti G, Palugan L, Gazzaniga A. Film coatings: A review. Oral pulsatile release. Int J Pharm 2013;457:362-71.
6. El-Maradny HA. Modulation of a pulsatile release drug delivery system using different swellable/rupturable materials. Drug Deliv 2007;14:539-46.
7. Ghimire M, McInnes FJ, Watson DG, Mullen AB, Stevens HN. In-vitro/in-vivo correlation of pulsatile drug release from press-coated tablet formulations. Eur J Pharm Biopharm 2007;67:515-23.
8. Pasham S, Venkatesh DP, Sujit N. Pulsatile drug delivery system: An overview. A formulation approach for the treatment of diseases. Int J Curr Pharm Res 2020;14:16-21.
9. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2001;18:433-58.
10. Santini JT, Scheidt RA, Cima R, Langer MJ, Angew R. ???. Chem Int Ed 2000;39:2397-407.
11. Prescott JH, Lipka S, Baldwin S, Sheppard NF, Maloney JM, Coppeta J, et al. Chronic, programmed polypeptide delivery from an implanted, multi-reservoir microchip device. Nat Biotechnol 2006;24:437-8.
12. Shidhaye S, Lotlikar V, Ghule A, Phutane P, Kadam V. Pulsatile delivery systems: An approach for chronotherapeutic diseases. Sys Rev Pharm 2010;1:5-61.
13. Richards Grayson AC, Choi IS, Tyler BM, Wang PP, Brem H, Cima MJ, et al. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2003;2:767-72.
14. Santini JT, Cima MJ, Langer R. A controlled-release microchip. Nature 1999;397:335-8.
15. Ritschel WA, Forusz H. Chronopharmacology: A review of drugs studied. Methods and findings in experimental and clinical pharmacology. EMBO J 1994;16:57-75.
16. Reddy JR, Jyothsna MV, Saleem TM, Chetty CM. Review on: Pulsatile drug delivery systems. J Pharm Sci Res 2009;1:109-15.
17. Yang SY, Yang JA, Kim ES, Jeon G, Oh EJ, Choi KY, et al. Single-file diffusion of protein drugs through cylindrical nanochannels. ACS Nano 2010;4:3817-22.
18. Jha N, Bapat S. Chronobiology and chronotherapeutics. KUMJ 2004;2:384-8.
19. Bruguerolle B, Lemmer B. Recent advances in chronopharmacokinetics: A review. Methodological problems. Life Sci 1993;52:1809-24.
20. Sarkhejiya NA, Praful DB. Newer insights into pulsatile drug delivery systems. WJPS 2017;5:134-50.
21. Youan BB. Chronopharmaceutics: Gimmick or clinically relevant approach to drug delivery? J Control Release 2004;98:337-53.
22. Chhabra VS, Shrikant KT, Walde SR, Abhay M. The essentials of chronopharmacotherapeutics. Int J Pharm Pharm Sci 2012;4:1-8.
23. Rompicharla B, Prabha KS, Tabasum M. A comprehensive review of pulsatile drug delivery system. Int Res J Pharm 2012;3:106-8.
24. Patil ND, Bari MM, Barhate SD. A review on novel approach pulsatile drug delivery system. Int J Pharm Sci Rev Res 2013;21:209-22.
25. Pandit V, Kumar A, Ashawat MS, Verma CP, Kumar P. Recent advancement and technological aspects of pulsatile drug delivery system-a laconic review. Curr Drug Targets 2017;18:1191-203.
26. Rathod S. Colon targeted pulsatile drug delivery: A review. Pharm net 2007;5:1-1.
27. Survase S, Kumar N. Pulsatile drug delivery: Current scenario. CRIPS 2007;8:27-33.
28. Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: The basis for the chronotherapy of hypertension. Adv Drug Deliv Rev 2007;59:904-22.
29. Janugade BU, Patil SS, Patil SV, Lade PD. Pulsatile drug delivery system for chronopharmacological disorders: An overview. J Pharm Res 2009;2:132-43.
30. Desai TR, Matholiya CR, Patel VP, Chhayani RB. Pulsatile drug delivery system: A review. Pharma Tutor 2015;2:1-30.
31. Sarasija S, Hota A. Colon-specific drug delivery systems. Indian J Pharm Sci 2002;62:1-8.
32. Kinget R, Kalala W, Vervoort L, Van den Mooter G. Colonic drug targeting. J Drug Target 1998;6:129-49.
33. Krögel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm Res 1998;15:474-81.
34. Wu F, Zhang ZR, He WL, Zhang Y. Preparation and in vitro release of tetramethylpyrazine phosphate pulsincap capsule controlled by an erodible plug. Acta Pharm Sin B 2002;37:733-8.
35. Crison JR, Siersma PR, Amidon GL. A novel programmable oral release technology: For delivering drugs. Bioact Mater 1996;23:51-2.
36. Pollock Dove C, Dong L, Wong PA. New system to deliver a delayed bolus of liquid drug formulation. Bioact Mater 2001;28:6033.
37. Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically driven delivery devices with pulsatile effect. U S Patent 5 1993;209:746-52.
38. Magruder PR, Barclay B, Wong PS, Theeuwes F. A composition comprising a therapeutic agent and a modulating agent. U S Patent 4 1989;851:229-310.
39. Maroni A, Sangalli ME, Cerea M, Busetti C, Giordano F, Gazzaniga A. Low viscosity HPMC coating of soft and hard gelatin capsules for delayed and colonic release: Preliminary investigations on process parameters and in vitro release performances. Bio Act Mater 1999;26:887-8.
40. Patel GN, Patel GC, Patel RB, Patel SS, Patel JK. Oral colon-specific drug delivery. Drug Deliv Technol 2006;6:62-71.
41. Gazzaniga A, Colombo P, Manna A, Conte U. A new ibuprofen pulsed release oral dosage form. Drug Dev Ind Pharm 1989;15:2583-96.
42. Krogel I, Bodmeier R. Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm 1999;187:175-84.
43. Ueda S, Yamaguchi H, Kotani M, Kimura S, Tokunaga Y, Kageyama AH, et al. development of a novel drug release system, time-controlled explosion system. Chem Pharm Bull 1994;42:359-63.
44. Beckert TE, Pogarell K, Hack I, Petereit HU. Pulsed drug release with film coatings of Eudragit and Mac226; RS 30D. Proc Int Symp Controlled Release Bioact 1999;26:533-34.
45. Dalvadia H, Patel JK. Chronpharmaceutics, pulsatile drug delivery system as the current trend. Asian J Pharm Sci 2010;5:204-30.
46. Oh KS, Han SK, Choi YW, Lee JH, Lee JY, Yuk SH. Hydrogen-bonded polymer gel and its application as a temperature-sensitive drug delivery system. Biomaterials 2004;25:2393-8.
47. Kataoka K, Miyazaki H, Bunya M. synthetic polymer gels responding to external glucose concentration: Their preparation and application to on-off regulation of insulin release. J Am Chem Soc 1998;120:12694-5.
48. Ishihara K, Kobayashi M, Ishimaru N, Shinohara I. Glucose-induced permeation control of insulin through a complex membrane consisting of immobilized glucose oxidase and a poly (amine). Polym J 1984;16:625-31.
49. Smith AW. Biofilms and antibiotic therapy: A review. Is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev 2005;57:1539-50.
50. Arora S, Ali J, Ahuja A, Baboota S, Qureshi J. Pulsatile drug delivery systems: An approach for controlled drug delivery. Indian J Pharm Sci 2006;68:295-300.
51. Yoshida R, Kaneko Y, Sakai K, Okano T, Sakurai Y, Bae YH, et al. Positive thermosensitive pulsatile drug release using negative thermosensitive hydrogels. J Control Release 1994;32:97-102.
52. Wood KC, Zacharia NS, Schmidt DJ, Wrightman SN, Andaya BJ, Hammond PT. Electroactive controlled release thin films. PNAS 2008;105:2280-5.
53. Kost J. Ultrasound for controlled delivery of therapeutics. Clin Mater 1993;13:155-61.
54. Hsieh DS, Langer R, Folkman J. Magnetic modulation of release of macromolecules from polymers. PNAS 1981;78:1863-7.
55. Hoare T, Timko BP, Santamaria J, Goya GF, Irusta S, Lau S, et al. Magnetically triggered nanocomposite membranes: A versatile platform for triggered drug release. Nano Lett 2011;11:1395-400.
56. Parmar RD, Parikh RK, Vidyasagar G, Patel DV, Patel CJ, Patel BD. Pulsatile drug delivery systems. IJPSN 2009;2:605-14.
57. Neurontin. United States: Pfizer Inc.; 2002-2009. Available from:
58. Fukada C, Kohler JC, Boon H, Austin Z, Krahn M. Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists. CPJ 2012;145:280-84.
59. Hema J, Vaseem AA, Pandit JN, Farogh A. Pulsatile drug delivery system: An overview with special emphasis on losartan and captopril. RJPT 2019;12:3175-88.
60. Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric-coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm 2000;204:7-15.
61. Jose S, Dhanya K, Cinu TA, Litty J, Chacko AJ. Colon targeted drug delivery: Different approaches. J Young Pharm 2009;1:1-13.
62. Patel GC, Patel MM. Developing a modified pulsincap system. Pharm Technol Eur 2009;21:13-9.
63. Steve E. Bioenhancement technologies improve absorption of insoluble drugs in oral dosage forms. Drug Deliv 2007;2:4.
64. Parcel PJ, Vishnupad KS, Venkatesh GM. Timed, sustained release systems for propranolol. US Patents 2002;31:1-10.
65. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: Current perspectives. J Control Release 2009;134:74-80.
66. Verma RK, Garg S. Current status of drug delivery technologies and future directions. Pharm Technol Eur 2001;25:1-14.
67. Yu DG, Zhu LM, Branford-White CJ, Yang XL. Three-dimensional printing in pharmaceutics: Promises and problems. J Pharm Sci 2008;97:3666-90.
68. Rowe CW, Katstra WE, Palazzolo RD, Giritlioglu B, Teung P, Cima MJ. multimechanism oral dosage forms fabricated by three-dimensional printing. J Control Release 2000;66:11-7.
69. Katstra WE. Fabrication of Complex Oral Drug Delivery Forms by Three Dimensional Printing. Cambridge, Massachusetts: MIT 2001. p. 237-41.
70. Patel R, Patel J. Novel technologies of oral controlled release drug delivery system. Sys Rev Pharm 2010;1:128.
71. Panoz DE, Geoghegan EJ. Controlled Absorption Pharmaceutical Composition. United States: US Patent; 1989.
72. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev 2013;64:15-29.
73. Lackner TE. Pharmacotherapy of urinary incontinence. J Am Med Dir Assoc 2002;3:16-24.
74. Rappar D. Oral extended-release: Snapshots and benefits. J Drug Deliv Sci Technol 2007;7:30-42.
75. Bhatt AD, Pethe AM. Nanotechnology: A promising drug delivery for poorly water-soluble drugs. J Pharm Res 2010;3:1748-51.
76. Shram M, Romach M, Sellers E, Thipphawong J. Assessing the abuse potential of an oral osmotic-controlled extended-release (OROS) hydromorphone compared to immediate-release hydromorphone. J Pain 2009;10:S45.
77. Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J Control Release 1985;1:269-82.
78. Dey NS, Majumdar S, Rao ME. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008;7:1067-75.
79. Rewar S, Bansal BK, Singh CJ, Sharma AK, Pareek R. Pulsatile drug delivery system: An overview. JGTPS 2014;5:1943-55.
80. SkyePharma-Drug Delivery Specialists; 2010. Available from:
81. Saigal N, Baboota S, Ahuja A, Ali J. Multiple-pulse drug delivery systems: Setting a new paradigm for infectious disease therapy. Expert Opin Drug Deliv 2009;6:441-52.
82. Shidhaye S, Dhone A, Budhkar T, Surve C. Technologies in pulsatile drug delivery system. IJAPBC 2012;1:438-45.
83. Conte U, Maggi L, Colombo P, La Manna A. Multi-layered hydrophilic matrices as constant release devices (GeomatrixTM Systems). J Control Release 1993;26:39-47.
84. Conte U, Magg L, La Manna A. Compressed barrier layers for constant drug release from swellable matrix tablets. STP Pharma Sci 1994;4:107-13.
85. Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix® multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996;17:889-96.
86. Conte U, La Manna A, Colombo P. Tablets with the Controlled Rate Release of Active Substances. United States: US Patent US 5; 1995.
87. Sakurai M, Ozeki Y, Ando M, Okamoto H, Danjo K. Preparation and release profile of colon-targeting drug delivered as novel one-step dry-coated tablets. J Pharm Soc Jpn 2007;127:2057-63.
88. Ozeki Y, Danjo K. Development of one-step dry-coated tablet system (OSDRC-System) and the comparison of its compression characteristics with those of conventional dry-coated tablets. J Pharm Sci Technol 2004;64:59-66.
89. Yuichi O, Masaki A, Yukinao W, Kazumi D. Evaluation of novel one-step dry-coated tablets as a platform for delayed-release tablets. J Cont Rele 2004;95:51-60.
90. Ozeki Y, Watanabe Y, Okamoto H, Danjo K. Development of dividable one-step dry-coated tablets (dividable-OSDRC) and their evaluation as a new platform for controlled drug release. Pharm Res 2004;21:1177-83.
91. Shaji J, Chadawar V, Talwalkar P. Multiparticulate drug delivery system. Indian J Pharm Sci 2007;6:21-8.
92. Eurand SP. Corporation Minitab’s in Multiparticulate Drug Delivery. ???: ???; 2003.
93. Lemmer B. Circadian rhythms and drug delivery. J Control Release 1991;16:63-74.
94. Modi MP, Prasanth VV, Mathew ST. pulsatile: A tool for circadian rhythm-a review. JDDT 2012;2:58-65.
95. Kamalpuria N, Dhir S, Jain S. The latest methods and technologies of pulsatile drug delivery system: A review. Int J Pharm Life Sci 2017;8:5446-58.
9 Views | 17 Downloads
How to Cite
R, V., and L. NALLAGUNTLA. “REVIEW ARTICLE ON PULSATILE DRUG DELIVERY SYSTEM”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 6, May 2021, pp. 48-59, doi:10.22159/ajpcr.2021.v14i6.41476.
Review Article(s)